NCT00000400View on ClinicalTrials.gov

Alendronate and/or Parathyroid Hormone for Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

April 30, 2006

Study Completion Date

June 30, 2006

Conditions
Osteoporosis
Interventions
DRUG

Human parathyroid hormone [hPTH-(1-34)]

37 mcg once daily by self-administered sc injection

DRUG

alendronate

70 mg/week by oral route

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00000400 - Alendronate and/or Parathyroid Hormone for Osteoporosis | Biotech Hunter | Biotech Hunter